Takeda to sell Japan consumer health unit valued at 242b yen to Blackstone
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
[TOKYO] Takeda Pharmaceutical said on Monday it has agreed to sell its Japanese consumer healthcare business to US investment fund Blackstone Group.
Takeda Consumer Healthcare Company, which makes over-the-counter (OTC) drugs and health products, is valued at 242 billion yen (S$3.13 billion) and the sale price will be determined after calculating its debt and other factors, Takeda said.
Japan's largest pharmaceuticals company has been reducing its OTC assets worldwide as it seeks to refocus its business and reduce debt following its US$59 billion acquisition of Shire.
Blackstone was among the final bidders for the OTC unit, Reuters reported in June, along with Bain Capital, CVC Capital Partners and Taisho Pharmaceutical.
Takeda said proceeds from the sale would boost its net profit by 105 billion yen. The transaction is expected close by March 31, subject to regulatory closing conditions, it said.
The deal follows Blackstone's acquisition of Japan's Ayumi Pharmaceutical Corp for US$1 billion in March 2019.
Navigate Asia in
a new global order
Get the insights delivered to your inbox.
REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
‘Boring’ is the new black: The stars are aligning for a Singapore stock market revival
Near sell-out launches in March boost developer sales to 1,300 units after four slow months
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Genting Singapore’s Lim Kok Thay receives S$7.5 million pay package for FY2025
